TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06376331
Drug: washed microbiota transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The prepared microbiota suspension was infused into the participates' lower gut.
Study: NCT05369676
Drug: SSD8432 dose 1/Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 1:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；
Study: NCT05369676
Drug: SSD8432 dose 2/Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 2:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；
Study: NCT02835131
Drug: Pasireotide
Normalized name: Pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04697056
Drug: Imsidolimab
Normalized name: Imsidolimab
DrugBank: Imsidolimab (DB16658)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humanized Monoclonal Antibody
Study: NCT05245682
Drug: Tolinapant
Normalized name: Tolinapant
DrugBank: Tolinapant (DB16160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05044091
Drug: PARP inhibitor
Normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian/fallopian tube/primary peritoneal cancer patients with PARP inhibitors according to the NCCN guideline and their instructions
Study: NCT04847466
Drug: N-803
Normalized name: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every 4 weeks (1 week after starting treatment with the PDL-1 CAR-NK cells).
Study: NCT04847466
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 400 mg will be administered as a 30-minute IV infusion every 6 weeks. Pembrolizumab will be administered on the same day as the PD-L1 CAR-NK cells.
Study: NCT05631964
Drug: BL-M07D1
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT05030428
Drug: Inclisiran sodium 300 mg
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
Study: NCT05676684
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A: Dapagliflozin 10 mg once daily
Study: NCT04840069
Drug: Fluciclovine PET guided Radiotherapy
Normalized name: Fluciclovine
DrugBank: Fluciclovine (18F) (DB13146)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PET+MRI Based There is no GTV_5400. The GTV_6000 will be defined as the surgical cavity inclusive of any remaining tumor enhancement and the hypermetabolic volume. CTV_5400 will include the GTV_6000 plus a margin of 1.0 cm which may be reduced around natural barriers to tumor growth such as the skull, ventricles, falx, etc. CTV_5400 must also include the entirety of the GTV_6000. There is no CTV_6000. PTV_5400 is the CTV_5400 plus a geometric 3 mm expansion in all dimensions; PTV_6000 is GTV_6000 plus a geometric 3 mm expansion in all dimensions. PTV may extend beyond bony margins and the skin surface. The PTV_5400 must contain the PTV_6000. In the setting of multi-focal disease, the primary target volumes will be defined as above, but for satellite lesions, the GTV_6000 will be defined as any tumor enhancement and hypermetabolic volume. There will be no CTV_6000. PTV_6000 will be defined as GTV_6000 plus a geometric 3 mm expansion in all dimensions.
Study: NCT06135402
Drug: Treatment with Clobetasol
DrugBank: Clobetasol (DB11750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of Clobetasol twice per week
Study: NCT06143774
Drug: TRX-920 Oral Gel (10 mg and 30 mg)
Normalized name: TRX-0237
DrugBank: Hydromethylthionine mesylate (DB16899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRX-920 Oral Gel will be administered orally at a week (BIW) in an 8-week cycle. No food should be taken 2 hours before and 1 hour after taking TRX-920. The dose escalation/de-escalation rules will be based on definitions of dose-limiting toxicity (DLT) and will be monitored during the first treatment cycle (i.e., the first 4 weeks post the first dose).~The starting dose will be 1 mg and the dosing frequency is twice every week (BIW). Subjects will be assigned to a dose level in sequential cohorts based on the order of their enrollment. The dose escalation will follow a 3+3 design and doses escalate from approximately 1 mg BIW, 2 mg BIW, 4 mg BIW, 8 mg BIW, and 16mg BIW and the doses for subsequent cohorts will be determined by Safety Review Committee (SRC). Dose escalation will be stopped till the maximum tolerated dose (MTD) is reached or identified.
Study: NCT04802070
Drug: Autologous CIK
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory (4 dose levels)
Study: NCT04667377
Drug: BI 456906
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 456906
Study: NCT04592744
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion for Intraoperative management during liver transplantation
Study: NCT06271486
Drug: Pregabalin 75mg
Normalized name: PREGABALIN 75MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Group A (pregabalin group) received oral pregabalin treatment administered at 150 mg daily, with 75 mg given every 12 hours.
Study: NCT05703555
Drug: Tusamitamab ravtansine
Normalized name: Tusamitamab ravtansine
DrugBank: Tusamitamab ravtansine (DB17448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects will receive Tusamitamab ravtansine (100mg/m2 IV Q2W). Subjects without evidence of disease progression or drug related toxicity can continue treatment with Tusamitamab ravtansine (100 mg/m2 IV Q2W) until disease progression, unacceptable toxicity occurs, or the participant's or Investigator's decision to stop the treatment.
Study: NCT06331598
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A dose of 1680 mg atezolizumab will be administered intravenously on Day 1 of each 28-day cycle for a total of 12 cycles.
Study: NCT06331598
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of 840 mg tiragolumab will be administered intravenously on Day 1 of each 28-day cycle for a total of 12 cycles.
Study: NCT06447454
Drug: gemcitabine + cisplatin
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000mg/m² intravenous infusion over 30 minutes, cisplatin 25mg/m² intravenous infusion, on day 1 and day 8, every 3 weeks.
Study: NCT06447454
Drug: slulimumab
Normalized name: Lulizumab pegol
DrugBank: Lulizumab pegol (DB15441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slulimumab, 4.5mg/kg intravenous infusion, Q3W
Study: NCT06481696
Drug: Follitropin Alfa
Normalized name: Follitropin Alfa
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled Ovarian Stimulation
Study: NCT06481696
Drug: Ganirelix Acetate 0.5 MG/ML [Fyremadel]
Normalized name: ganirelix acetate 0.5 MG/ML [Fyremadel]
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH Antagonist
Study: NCT06481696
Drug: hCG 10.000 IU or triptorelin 0,3 mg, subcutaneously
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For the induction of oocyte maturation
Study: NCT05360368
Drug: HLX07
Normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Recombinant Humanized Anti-EGFR Monoclonal Antibody, HLX07 will be administered as a single intravenous (IV) infusion on Day 1 in each 3-week cycle
Study: NCT05582681
Drug: Glecaprevir and Pibrentasvir
Normalized name: glecaprevir and pibrentasvir
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G/P will be provided for 8 weeks.
Study: NCT05429827
Drug: Dextrose 5% in water
Normalized name: LVP solution Dextrose 5% in Water intravenous solution
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inject 2 ml 5% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.
Study: NCT05429827
Drug: Dextrose 15% in water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inject 2 ml 15% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.
Study: NCT05002465
Drug: 68Ga-PSMA-11
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 68Ga PSMA-11
Study: NCT05797662
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adults: Propanolol 120 mg tablets by mouth twice daily for up to 24 weeks Children: Propanolol 3 mg/kg suspension, divided dose twice daily for up to 24 weeks
Study: NCT00000663
Drug: CD4-IgG
Normalized name: Human IGG
DrugBank: Recombinant human CD4 immunoglobulin G (DB17812)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04979520
Drug: Brodalumab
Normalized name: Brodalumab
DrugBank: Brodalumab (DB11776)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneously Brodalumab/Siliq, 210mg/1.5ml once a week
Study: NCT04986995
Drug: Opicapone
Normalized name: opicapone
DrugBank: Opicapone (DB11632)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
Study: NCT05389449
Drug: Danicopan
Normalized name: Danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06548100
Drug: mibavademab
Normalized name: Mibavademab
DrugBank: Mibavademab (DB16673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous (IV) infusion followed by subcutaneous (SC) injection
Study: NCT05738629
Drug: Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by PSC-MSC-Exo eye drops 0.125 ml/single eye/one time, four times a day for 12 weeks. The follow-up visit will be 12 weeks since the administration of PSC-MSC-Exo eye drops.
Study: NCT05426798
Drug: TQB2618 injection azacitidine, AZA decitabine, DAC
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug1: TQB2618 injection is a novel tim-3 inhibitor.~Drug2: Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DeoxyriboNucleic Acid methyltransferases at low doses, resulting in gene promoter hypomethylation.~Drug3: Decitabine is a cytidine deoxy nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.
Study: NCT06161272
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single
Study: NCT06161272
Drug: Fluzoparib+Apatinib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination
Study: NCT04794088
Drug: Imatinib Mesylate intravenous solution
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 200mg imatinib (100mg/h).
Study: NCT00002078
Drug: Interferon alfa-n3
Normalized name: Interferon alfa-n3
DrugBank: Interferon alfa-n3 (DB00018)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04979442
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.5 mg/m2 body surface area as a 24-hour IV infusion, every 3 weeks
Study: NCT00000808
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05642780
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle;
Study: NCT05211336
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab 1000 mg IV (intravenous) days 1 and 2 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
Study: NCT05211336
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 100 mg PO (by mouth) daily days 1-7 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
Study: NCT05211336
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 10 or 15 mg PO (by mouth) on days 1-14 for 1 cycle (21 days); followed by Lenalidomide 10 or 15 mg PO daily days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
Study: NCT05211336
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax 800 mg PO (by mouth) on days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
Study: NCT05211336
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib 560 mg PO (by mouth) daily days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
Study: NCT05863975
Drug: Human interferon alpha 2b vaginal Effervescent capsules
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ①Interferon group: human interferon alpha 2b vaginal effervescent capsule vaginal medication. ② Promestriene group: promestriene cream vaginal medication. ③Interferon + promestriene combination group: two drugs were given in combination.
Study: NCT05467215
Drug: Pure oxygen (99%) from Praxair, Edmonton, DIN# 02014408
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive oxygen (99%) or room air (placebo) delivered through a face mask at a flow rate of 10 litres/min for 2 minutes. The participants will be exposed twice to both conditions over 4 experiments at a minimum of 2 week intervals between each testing session.
Study: NCT05283304
Drug: Buprenorphine injection (BUP-Inj)
Normalized name: buprenorphine Injection
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sublingual Buprenorphine induction, then SublocadeTM, Indivior injectable (300mg)
Study: NCT04686175
Drug: INZ-701
Normalized name: INZ-701
DrugBank: INZ-701 (DB17629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INZ701-101 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
Study: NCT05708950
Drug: KVA12123 - Dose Escalation
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending KVA12123 doses given as monotherapy by intravenous administration every 2 weeks of each 6-week cycle.
Study: NCT05708950
Drug: KVA12123 Plus Pembrolizumab - Dose Escalation
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ascending KVA12123 doses given by intravenous administration every 2 weeks of each 6-week cycle in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.
Study: NCT05708950
Drug: KVA12123 - Dose Expansion
Normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KVA12123 administered at the RP2D by intravenous administration every 2 weeks of each 6 week cycle.
Study: NCT05708950
Drug: KVA12123 Plus Pembrolizumab - Dose Expansion
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: KVA12123 administered at the RP2D by intravenous administration every 2 weeks in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.
Study: NCT05013034
Drug: Basiliximab Injection
Normalized name: basiliximab Injection
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be given IV dosing with basiliximab up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
Study: NCT04872400
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 vial of Vancomycin 1g powder applied topically to the open fracture wound injury.
Study: NCT06066424
Drug: Rimiducid
Normalized name: Rimiducid
DrugBank: Rimiducid (DB04974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by (IV) vein
Study: NCT06066424
Drug: TROP2-CAR-NK Cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by (IV) vein
Study: NCT06066424
Drug: Fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by (IV) vein
Study: NCT04298983
Drug: Abemaciclib 150 MG by mouth twice daily
Normalized name: abemaciclib 150 MG
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abemaciclib will start with initiation of ADT, 3 months before RT, and pause 2 weeks prior to start of RT. Abemaciclib will resume with the first ADT administration post-radiation, which is about 1 month post radiation therapy. Abemaciclib will continue for a total of 24 months.
Study: NCT05529927
Drug: Sustained-release Dexamphetamine
Normalized name: dextroamphetamine Extended Release Oral Capsule
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the first week, patients will be individually titrated to the target dose of 90 mg/day, if tolerated. From the second week onwards, patients are prescribed 3 tablets (30 mg) per day, if tolerated. Titration can be slower but should be finished at the end of week 4. After 4 weeks dosages can no longer be increased, and only be reduced.~Patients will visit the treatment centre 2 times per week to take their study medication under supervision of the treatment staff and to receive take-home medication for the days in between study visits.~After 24 weeks patients will be randomized to either (double-blind) continuation or discontinuation (placebo) of SR-Dexamphetamine treatment to assess the consequences of discontinuation, during a 6 weeks period.
Study: NCT04996797
Drug: Tulisokibart
Normalized name: Tulisokibart
DrugBank: Tulisokibart (DB18719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IV infusion
Study: NCT06256510
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive a single dose of Midazolam by mouth in Period 1 Day 1, and Period 2 Day 1 and Day 15
Study: NCT06256510
Drug: Vepdegestrant
Normalized name: Vepdegestrant
DrugBank: Vepdegestrant (DB19006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Vepdegestrant by mouth once a day for 15 days in Period 2.
Study: NCT05893537
Drug: Active Comparator CT1812
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 123 participants will receive a single daily dose of CT1812 (200 mg)
Study: NCT05768919
Drug: Treatment Period 2
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Weeks 7,8,9,10 Cycle length: 4 weeks
Study: NCT05768919
Drug: Treatment Period 4a
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: 35+ Weeks 1, 2, 3, 4 of each cycle Cycle Length: 4 weeks
Study: NCT05548738
Drug: prolotherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a type of hypertonic glucose
Study: NCT05170828
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pre-transplant conditioning treatment
Study: NCT05170828
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pre-transplant conditioning treatment
Study: NCT05170828
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given with cyclophosphamide
Study: NCT05170828
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: post-transplant treatment for GVHD
Study: NCT05170828
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: post-transplant treatment for GVHD
Study: NCT05170828
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: post-transplant treatment for GVHD
Study: NCT05593250
Drug: SHR-1905
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous
Study: NCT06195319
Drug: Simufilam
Normalized name: Simufilam
DrugBank: Simufilam (DB18817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of \[14C\]-simufilam
Study: NCT05620641
Drug: Ondansetron 8mg
Normalized name: ONDANSETRON 8MG ORAL DISINTEGRATING TAB
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 patients will receive intravenous ondansetron 8 mg before the end of surgery.
Study: NCT05620641
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 patients will receive 600 mg oral gabapentin 1 h before anesthesia.